This represents a potential therapeutic vulnerability, as the H3K27Ac is bound by BRD4, which can be targeted by BET inhibitors to result in antitumor effects in MCC (214–216); however, the Myc-dependency of this effect has been debated (215). The gene discussed is MYC; the disease is Merkel cell skin cancer.